Skip to main content

ADVERTISEMENT

bioresorbable vascular scaffold

Clinical Images
03/01/2023
This case of a 72-year-old gentleman presenting with angina and moderate stenosis demonstrates the ability to image a target vessel non-invasively and revascularize percutaneously or surgically with bioresorbable vascular scaffolds.
This case of a 72-year-old gentleman presenting with angina and moderate stenosis demonstrates the ability to image a target vessel non-invasively and revascularize percutaneously or surgically with bioresorbable vascular scaffolds.
This case of a 72-year-old...
03/01/2023
Journal of Invasive Cardiology
Original Contribution
06/06/2021
The study objective is to compare the major adverse cardiovascular event rates after implantation of BVS, first-generation DES, and BMS.
The study objective is to compare the major adverse cardiovascular event rates after implantation of BVS, first-generation DES, and BMS.
The study objective is to...
06/06/2021
Journal of Invasive Cardiology
Comparison Between Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Bioresorbable Vascular Scaffolds
06/01/2021
The study objective is to compare the major adverse cardiovascular event rates after implantation of BVS, first-generation DES, and BMS.
The study objective is to compare the major adverse cardiovascular event rates after implantation of BVS, first-generation DES, and BMS.
The study objective is to...
06/01/2021
Journal of Invasive Cardiology
Original Contribution
10/01/2015
The bioresorbable vascular scaffold (BVS) (Abbott Vascular) provides temporary scaffolding while eluting everolimus. The current study aims to investigate the safety and efficacy of BVS implantation in a selected patient cohort (n = 70) with...
The bioresorbable vascular scaffold (BVS) (Abbott Vascular) provides temporary scaffolding while eluting everolimus. The current study aims to investigate the safety and efficacy of BVS implantation in a selected patient cohort (n = 70) with...
The bioresorbable vascular...
10/01/2015
Journal of Invasive Cardiology
06/29/2015
The optimal treatment for recurrent in-stent restenosis (ISR) is uncertain. The authors describe a feasible combined treatment for recurrent ISR using neointimal debulking and ablation of underexpanded stents by rotational atherectomy...
The optimal treatment for recurrent in-stent restenosis (ISR) is uncertain. The authors describe a feasible combined treatment for recurrent ISR using neointimal debulking and ablation of underexpanded stents by rotational atherectomy...
The optimal treatment for...
06/29/2015
Journal of Invasive Cardiology
Original Contribution
02/01/2015
Experience with bioresorbable vascular scaffolds (BVSs) outside clinical trials is scarce, and data from “real-world” use are needed. In particular, there are few data on scaffold thrombosis (ST); we report our experience with ST in our...
Experience with bioresorbable vascular scaffolds (BVSs) outside clinical trials is scarce, and data from “real-world” use are needed. In particular, there are few data on scaffold thrombosis (ST); we report our experience with ST in our...
Experience with bioresorbable...
02/01/2015
Journal of Invasive Cardiology
Clinical Images
11/26/2014
We describe one of the first cases of bioresorbable vascular scaffold restenosis. We treated it like a drug-eluting stent restenosis, performing first an intracoronary optical coherence tomography scan in order to identify the left descending...
We describe one of the first cases of bioresorbable vascular scaffold restenosis. We treated it like a drug-eluting stent restenosis, performing first an intracoronary optical coherence tomography scan in order to identify the left descending...
We describe one of the first...
11/26/2014
Journal of Invasive Cardiology